Searched for
BRIAN TEMPEST
Fortis shortlists 4 entities for business saleIn a regulatory filing, Fortis said it has received interest from various parties on May 31.- Truncated Fortis Board to consider all previous bidsIf the board decides to re-examine the bids, it would render infructuous the decision to recommend the Munjal-Burmans bid to shareholders f...
- Fortis shareholders vote to oust Brian Tempest from the company's boardThe development comes while Fortis is yet to ratify a proposal from a consortium of Sunil Kant Munjal of Hero Enterprises and the Burman fa...
- Split Fortis Board didn’t heed its advisers on saleInvestors such as Eastbridge and Jupiter along with Rakesh Jhunjhunwala, representing 13% of the firm, have questioned the credibility of o...
- Manipal-TPG disappointed with Fortis decision to choose Munjal-Burman bid“After many months of engagement with Fortis, including due diligence, we are disappointed that the board has come to this conclusion," sta...
- Fortis Healthcare’s board forms expert panel to assess binding bidsFortis is legally required to hold an EGM as sought by stakeholders National Westminster Bank Plc, East Bridge Capital Master Fund Ltd and ...
- Buy Glenmark Pharmaceuticals, target Rs 610: Manas JaiswalBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 610.0 and a stop loss at Rs 567 from the entry point.
- Buy Glenmark Pharmaceuticals, target Rs 580: Dr CK NarayanBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 580.0 and a stop loss at Rs 560 from entry point.
- Sell Glenmark Pharmaceuticals, target Rs 532: Pritesh MehtaSell Glenmark Pharmaceuticals Ltd. at a price target of Rs 532.0 and a stop loss at Rs 582 from entry point.
- Buy Glenmark Pharmaceuticals, target Rs 666: Kunal BothraBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 666.0 and a stop loss at Rs 615 from entry point.
- Buy Glenmark Pharmaceuticals, target Rs 651: Pritesh MehtaBuy Glenmark Pharmaceuticals Ltd. at a price target of Rs 651.0 and a stop loss at Rs 603 from entry point.
- Buy Fortis Healthcare, target Rs 180: Kunal BothraBuy Fortis Healthcare Ltd. at a price target of Rs 180.0 and a stop loss at Rs 160 from entry point.
- Buy Fortis Healthcare, target Rs 170: Kunal BothraBuy Fortis Healthcare Ltd. at a price target of Rs 170.0 and a stop loss at Rs 153 from entry point.
- Buy Fortis Healthcare, target Rs 172: Pritesh MehtaBuy Fortis Healthcare Ltd. at a price target of Rs 172.0 and a stop loss at Rs 152 from entry point.
- Buy Fortis Healthcare, target Rs 165: Kunal BothraBuy Fortis Healthcare Ltd. at a price target of Rs 165.0 and a stop loss at Rs 142 from entry point.
- Sell Fortis Healthcare, target Rs 130: Manas JaiswalSell Fortis Healthcare at a price target of Rs 130 and a stop loss at Rs 143.50 from entry point.
- Ranbaxy Laboratories rejigs board, Malvinder is chairmanRanbaxy Laboratories and its new owner Japan’s Daiichi Sankyo on Friday reconstituted a new 10-member board.
- Here's someone who bet on India 12 years backHis UK colleagues were bemused by his choice, but Brian Tempest saw big potential in India.
- Generic firms & innovators tie up to cut legal costsIn these settlements, the generic company typically agrees to delay its entrance in the market in exchange for certain benefits. Lifestyle ...
- India ahead of China in global pharma industryIndia was better positioned than China on various parameters to reach the centre stage in the global pharma industry, but needed to address...
Load More
